Corporate News & Info - Press Releases

Press Releases

Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine
Axela Inc., an innovator in systems for multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip.

Axela Inc. announces bilateral agreement with diagnostic provider Salomao and Zoppi and Cria Opportunities Inc.
Axela Inc, the Toronto-based producer of multiplex biomarker tools for proteins, DNA and RNA in research and diagnostics, Salomao and Zoppi (S&Z), one of the largest diagnostics providers in Sao Paulo Brazil, and innovations management firm Cria Opportunities Inc (CRIA), have signed a memorandum of understanding to commercialize Axela’s technology in Brazil and South America.

Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
Xceed Molecular announced that it has met the goals of a $127,000 HTX/CIHR grant, reducing sample-preparation time from 2.5 days to less than eight hours.

James L. Wittliff, Ph.D., FACB, to Present "Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex® System at the Association for Molecular Pathology Conference, October 30
Xceed Molecular announced that renowned breast cancer researcher and Xceed collaborator, Dr. James L. Wittliff, a professor in the Department of Biochemistry and Molecular Biology at the University of Louisville, will be a featured speaker at the Association for Molecular Pathology (AMP) Annual Meeting.

Mt. Sinai Services Toronto Becomes An Xceed Authorized Gene-Expression Service Provider Using Ziplex® System
Xceed Molecular announced that the Mt. Sinai Services unit of the Mt. Sinai Hospital in Toronto, Canada, has become an authorized provider of gene-expression services using Xceed's
Ziplex System.
Queen's University Chooses Xceed's Ziplex® System for Translational Research
Xceed Molecular announced that Queen's University in Kingston, Ontario, Canada, is the latest high-profile institution to implement Xceed's Ziplex System as a critical tool to advance its translational research.

Xceed Ziplex® System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
Xceed Molecular announced that R&D Magazine has selected the company's Ziplex System as a recipient of the magazine's prestigious R&D 100 Award.

Xceed Molecular to Launch New Inflammation Xpress Chip™ for the Ziplex® Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Xceed Molecular will launch its new Inflammation Xpress Chip, a pre-configured array for use with the company’s Ziplex automated gene-expression analysis system, at the 2008 AACC/ASCLS Clinical Lab Expo (booth 2155).

Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
Xceed Molecular announced that the Mt. Sinai Services unit of the Mt. Sinai Hospital in Toronto, Canada, has become an authorized provider of gene-expression services using Xceed's
Ziplex System.
Xceed Molecular Grants Gen-Probe License to Xceed's Flow-Thru Chip® Technology for Multiplex Molecular Diagnostics
Xceed Molecular has granted Gen-Probe Incorporated (Nasdaq: GPRO) and its affiliates a non-exclusive license to use Xceed's novel Flow-Thru Chip technology.

Xceed Molecular Features Ziplex® Automated Gene-Expression System at the Biomarker World Congress, Booth 16
Xceed's Dr. David Englert and Dr. Zhe Zhang of Children's Hospital of Philadelphia will present data at a luncheon workshop on Wednesday, May 21st

Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Xceed Molecular announced that the University of Florida has joined Xceed's Strategic Collaborator program. Xceed will work with primary researchers, Charles Joel Rosser, MD (Department of Urology) and Steve Goodison, MD (Department of Surgery), to perform initial verification and validation of an expression signature that has shown promise as a way to differentiate bladder cancer from other conditions using voided urine samples.

Xceed Molecular Launches Strategic Collaborator Program; Signs Center for Molecular Medicine as its Inaugural Partner
Xceed Molecular announced that the company has launched its Strategic Collaborator program and signed its first member, the Center for Molecular Medicine (CMM), of Grand Rapids, Michigan. Specific terms were not disclosed.
Xceed Molecular Launches Ziplex® Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Xceed Molecular announced that the company will launch its Ziplex Automated Gene Expression System for research use only at the Association for Molecular Pathology (AMP) Annual Meeting and Exhibit, which opens today at the Hyatt Regency Century Plaza Hotel in Los Angeles.

Xceed Molecular Names Fran Tuttle to its Board of Trustees
Xceed Molecular Corporation announced today that Fran Tuttle has been appointed to Xceed’s board of directors.
Xceed Molecular to Debut RUO Ziplex Array
One year after rechristening itself Xceed Molecular to emphasize its orientation towards the clinical diagnostics market, the company formerly known as Metrigenix is preparing to launch a low-throughput and relatively affordable microarray platform called Ziplex next month.

Xceed Molecular names David Deems President, and Michael L. Cohen, Chairman of the Board.
Xceed Molecular announced today that David Deems has been appointed company president with full executive responsibility for strategic, commercial, and operational development,
effective immediately.

Appointment of Susan Bromley
Susan Bromley Named Vice President Diagnostic Product Development of MetriGenix, Inc.

MetriGenix Completes Acquisition of GeneXP Biosciences
MetriGenix, Inc. announced that it has completed the acquisition of Woburn, Massachusetts-based GeneXP Biosciences, Inc.